Ra Medical Systems, an excimer lasers and catheters developer, has secured clearance from the US Food and Drug Administration (FDA) to market its new laser radiation ablation (DABRA) system for the treatment of peripheral artery disease (PAD).

Designed as a less-expensive and safer solution, DABRA eliminates blockages from arteries in the limbs and is effective on all types of lesions.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

In addition to altering the arteries, the new system can bypass the lesion and cross the chronic total occlusions (CTOs) with a wire.

Ra Medical Systems co-founder and chief executive officer Dean Irwin said: “DABRA’s US market clearance is the realisation of more than a decade of dedication to the pursuit of delivering a more effective, safer and less expensive way to remove blockages from arteries to save limbs and, ultimately, save lives.

"DABRA’s US market clearance is the realisation of more than a decade of dedication to the pursuit of delivering a more effective, safer and less expensive way to remove blockages from arteries to save limbs and, ultimately, save lives."

“To do so, we built Ra Medical Systems and pioneered our cost-effective, small and portable Pharos excimer laser for dermatological diseases, creating our company infrastructure and self-funding the development of DABRA.”

See Also:

Expected to result in interventional procedures and better patient access, DABRA is said to require less procedural time, when compared to existing arterial blockage treatments.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The wireless system is considered to be safe as it remains in the patient’s true lumen and does not require subintimal access or perforation.

Its safety profile was confirmed in a clinical study, which demonstrated 95% positive outcome without clinically significant adverse events.